Clinical trials: CRS
Heart Failure; With Decompensation, Cardiorenal Syndrome
The Aortix CRS Pilot Study
The Aortix CRS Pilot Study: An Evaluation of the Safety and Performance of the Aortix System for Intra-Aortic Mechanical Circulatory Support in Patients with Cardiorenal Syndrome
- Conditions
- Heart Failure; With Decompensation, Cardiorenal Syndrome, Cardio-Renal Syndrome, Heart Failure
- Trial name
- NCT04145635
- Testing
- Aortix System
- Where
- 19 sites in United States, Australia
- Volunteers
- 21 people
- Sponsor
- Procyrion
Chronic Rhinosinusitis
Paclitaxel-Coated Nasal Balloon for the Treatment of Recurrent Chronic Rhinosinusitis With or Without Nasal Polyps (FIH)
It is a first in human (FIH) study to evaluate safety, and potential efficacy of Airiver Nasal DCB in the treatment of recurrent CRSwNP or CRSsNP. Participants will receive AIRIVER Nasal drug-coated balloon treatment.
- Trial name
- NCT05883462
- Testing
- Airiver Nasal Drug Coated Balloon (DCB) Catheter.
- Where
- Paraguay
- Volunteers
- 45 people
- Sponsor
- Airiver Medical, Inc.
Cytokine Release Syndrome (CRS) in Patients With COVID-19-induced Pneumonia
Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia
This was a multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of canakinumab plus standard-of-care (SOC) compared with placebo plus SOC in patients with COVID-19-induced pneumonia…
- Trial name
- CAN-COVID (NCT04362813)
- Testing
- Canakinumab
- Where
- 39 sites in United States, France and 4 more
- Volunteers
- 454 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Sinusitis, Chronic Rhinosinusitis (Diagnosis)
LYR-220 for Adult Subjects With Chronic Rhinosinusitis (BEACON Study)
This study will assess the safety, tolerability, pharmacokinetics and efficacy of two LYR-220 designs in symptomatic adult chronic rhinosinusitis (CRS) subjects who have had a prior functional endoscopic sinus surgery.
- Trial name
- NCT05035654
- Testing
- LYR-220 Design 1 (Part 1 only), LYR-220 Design 2 (Part 1 and Part 2)
- Where
- 25 sites in United States, Australia
- Volunteers
- 48 people
- Sponsor
- Lyra Therapeutics
Acute Lymphoblastic Leukemia, CD19 Positive
CD19 CAR-T Cells With CRS Suppression Technology for r/r CD19+ Acute Lymphoblastic Leukemia
This is a single center,randomized ,two-cohorts, open-label ,phase 1/2 study to evaluate the efficacy and safety of T cells expressing CD19 chimeric antigen receptors treatment for relapsed/refractory CD19+ acute lymphoblastic…
- Conditions
- Acute Lymphoblastic Leukemia, CD19 Positive, Relapse, Refractory
- Trial name
- NCT03275493
- Testing
- CD19 CAR-T cells, CD19 CAR-T cells with CRS suppression technology
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Chronic Sinusitis
A Clinical Evaluation of the Sinexus Intranasal Splint Following Functional Endoscopic Sinus Surgery in Patients With Chronic Rhinosinusitis
The purpose of this study is to assess the safety and performance of the Sinexus Intranasal Splint when used following Functional Endoscopic Sinus Surgery (FESS) in patients with Chronic Rhinosinusitis.
- Trial name
- CONSENSUS II (NCT00840970)
- Testing
- non-coated Intranasal Splint, Sinexus Intranasal Splint
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Intersect ENT
Chronic Rhinosinusitis (CRS)
Propel Drug-Eluting Sinus Implant Family IBUKI Cohort
To confirm clinical safety and performance for the PROPEL family of products when used according to IFUs and standard of care in Japan.
- Trial name
- NCT07546682
- Testing
- None, observational standard of care study
- Where
- Japan
- Volunteers
- 100 people
- Sponsor
- Medtronic
Chronic Rhinosinusitis (CRS), Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps
Evaluation of the Safety and Performance of a Bioresorbable Nasal Dressing Containing Mometasone Furoate (MF)
The primary objective of the study is to evaluate the safety and effectiveness of OCEAN as an adjunct aid in wound healing after nasal/sinus surgery and to demonstrate that OCEAN is non-inferior compared to a steroid-eluting…
- Trial name
- ENHANCE II (NCT07286201)
- Testing
- OCEAN, Steroid-eluting sinus stent
- Where
- 9 sites in United States
- Volunteers
- 110 people
- Sponsor
- Polyganics BV
Heart Failure, Congestive
Randomized Trial for Patients With Chronic Heart Failure With Acute Decompensation
The Company's proprietary products are based on Orqis Medical's hypothesis, supported by early clinical data, that increasing and maintaining continuous blood flow in the descending aorta, known as continuous aortic flow…
- Trial name
- NCT00357591
- Testing
- Continuous Aortic Flow Augmentation
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Orqis Medical Corporation
Chronic Sinus Infection
Sinopsys Lacrimal Stent Study for Patients With Chronic Sinusitis or CRS
A prospective, single arm, multicenter study designed to demonstrate that the Sinopsys® Lacrimal Stent can safely create transcaruncular access to the ethmoid sinus to enable sinus irrigation and reduce symptoms in patients with…
- Trial name
- CRS (NCT03066908)
- Testing
- Sinopsys® Lacrimal Stent
- Where
- 6 sites in United States
- Volunteers
- 4 people
- Sponsor
- Sinopsys Surgical
Cholangiocarcinoma
Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)
The purpose of this study is evaluate the efficacy of pemigatinib in subjects with advanced/metastatic or surgically unresectable cholangiocarcinoma with FGFR2 translocation who have failed at least 1 previous treatment.
- Trial name
- NCT02924376
- Testing
- Pemigatinib
- Where
- 120 sites in United States, Belgium and 10 more
- Volunteers
- 147 people
- Sponsor
- Incyte Corporation
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations
Infigratinib is an oral drug which selectively binds to fibroblast growth factor receptor (FGFR) 1-3. This is a multicenter, open-label, single arm phase IIa study to evaluate the efficacy and safety of Infigratinib in subjects…
- Conditions
- Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Solid Tumor
- Trial name
- FGFR (NCT05019794)
- Testing
- Infigratinib
- Where
- 17 sites in China
- Volunteers
- 80 people
- Sponsor
- LianBio LLC